Recurrent and/or Metastatic Head and Neck Squamou

A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the
Safety and Efficacy of Oral NRC-2694-A in Combination with Paclitaxel in
Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell
Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor
Therapy

Schedule an Appointment

Select an appointment date and time from available spots listed below.